An evolutionary approach for solving the job shop scheduling problem in a service industry

In this paper, an evolutionary-based approach based on the discrete particle swarm optimization (DPSO) algorithm is developed for finding the optimum schedule of a registration problem in a university. Minimizing the makespan, which is the total length of the schedule, in a real-world case study is considered as the target function. Since the selected case study has the characteristics of job shop scheduling problem (JSSP), it is categorized as a NP-hard problem which makes it difficult to be solved by conventional mathematical approaches in relatively short computation time

A solution-based intelligent tutoring system integrated with an online game-based formative assessment: development and evaluation

Nowadays, intelligent tutoring systems are considered an effective research tool for learning systems and problem-solving skill improvement. Nonetheless, such individualized systems may cause students to lose learning motivation when interaction and timely guidance are lacking. In order to address this problem, a solution-based intelligent tutoring system (SITS) is integrated with an online game-based formative assessment game called tic-tac-toe quiz for single-player (TRIS-Q-SP) for learning computer programming. This assessment game combines tic-tac-toe with online assessment, and the rules of tic-tac-toe are revised to stimulate students to use online formative assessment actively. Finally, an experimental study is devised to assess the success of SITS, and significant achievements are observed for the experimental group, besides enjoyment and positive opinions toward the TRIS-Q-SP. Therefore, the practical use of SITS is supported, as the results indicate considerable advantages for the experimental group over the control group. The findings also reveal that immediate elaborated feedback upon answering each question in TRIS-Q-SP is part of an optimal design

Short-term wind speed forecasting by an adaptive network-based fuzzy inference system (ANFIS): an attempt towards an ensemble forecasting method

Accurate Wind speed forecasting has a vital role in efficient utilization of wind farms. Wind forecasting could be performed for long or short time horizons. Given the volatile nature of wind and its dependent on many geographical parameters, it is difficult for traditional methods to provide a reliable forecast of wind speed time series. In this study, an attempt is made to establish an efficient adaptive network-based fuzzy interference (ANFIS) for short-term wind speed forecasting. Using the available data sets in the literature, the ANFIS network is constructed, tested and the results are compared with that of a regular neural network, which has been forecasted the same set of dataset in previous studies. To avoid trial-and-error process for selection of the ANFIS input data, the results of autocorrelation factor (ACF) and partial auto correlation factor (PACF) on the historical wind speed data are employed. The available data set is divided into two parts. 50% for training and 50% for testing and validation. The testing part of data set will be merely used for assessing the performance of the neural network which guarantees that only unseen data is used to evaluate the forecasting performance of the network. On the other hand, validation data could be used for parameter-setting of the network if required. The results indicate that ANFIS could not outperform ANN in short-term wind speed forecasting though its results are competitive. The two methods are hybridized, though simply by weightage, and the hybrid methods shows slight improvement comparing to both ANN and ANFIS results. Therefore, the goal of future studies could be implementing ANFIS and ANNs in a more comprehensive ensemble method which could be ultimately more robust and accurat

MGMT methylation alterations in brain cancer following organochlorine pesticides exposure

Background: Alterations in the methylation levels of tumor suppressor genes are considered as one of the essential aspects of malignancies. The present study explored the association of O6-methylguanine- DNA methyltransferase (MGMT) gene promoter methylation, as a tumor suppressor, with some organochlorine pesticides (OCPs) in primary brain tumor (PBT) patients. Methods: The present study was conducted on a total of 73 PBT patients. The patients’ serum was analyzed using gas chromatography for seven OCP derivatives. The methylation-specific PCR (MSP) method was also used to determine the methylation status of the MGMT promoter. Results: The current findings demonstrated that the methylation of MGMT promoter occurred in 22 out of 34 glioma cases (64%), but in only one out of 35 meningioma cases. No MGMT promoter methylation was observed in other PBT, hemangioma, and anaplastic medulloblastoma stages. Besides, there were significant associations between MGMT methylation and γ-HCH (odds ratio [OR]: 1.50; 95% CI: 1.03- 2.40, P = 0.04), 4,4DDE (OR: 1.44; 95% CI: 1.01- 2.05, P = 0.02), 2,4 DDT (OR: 1.23; CI: 1.04- 1.45, P = 0.03), and 4,4DDT (OR: 1.46; CI: 1.23- 2.15, P = 0.02) in glioma patients. Conclusion: The results of the study suggested that the hypermethylation of the MGMT promoter in glioma patients is associated with increased OCPs in their serum, especially γ- HCH, 4,4DDE, 2,4DDT, and 4,4DDT. Moreover, it may lead to the hypermethylation of the MGMT promoter gene. Hence, it can be concluded that exposure to OCPs may potentially induce glioma. Keywords: Organochlorine, Pesticides, MGMT, DNA Methylation, Gliom

Germination of Triticum aestivum L.: Effects of soil–seed interaction on the growth of seedlings

© 2022 The Authors. Published by MDPI. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.3390/soilsystems6020037Seed size, sowing depth, and seed disinfection can affect seed germination and seedling establishment, which, in turn, can directly affect crop growth and yield. The current study was comprised of two experiments, the first of which was conducted in the laboratory, and a second which was performed under glasshouse conditions. The objective of these experiments was to investigate the effects of seed size, sowing depth, and seed disinfection on seed germination and initial seedling growth of selected wheat (Triticum aestivum L.) cultivars. The treatments in laboratory experiment were arranged in a completely randomized design, which included: (Ι) four wheat cultivars (Pishgam, Haydari, Soissons, and Mihan), (ΙΙ) two seed size classes (x < 2.25 mm, and x > 2.25 mm), and two disinfection treatments (no-disinfection and disinfection), (ΙΙΙ) with five replicates. In addition to the aforementioned treatments, the effect of planting depth (4, 6, and 8 cm) was also investigated in the subsequent glasshouse experiment. The best results were obtained at a sowing depth of 4 cm, in the non-disinfected treatment, using large seeds. In contrast, the lowest percentage and speed of seed germination and vigor index were observed in seeds sown at 8 cm depth, in the disinfected seed treatment, using small seeds. Large seeds contain larger nutrient stores which may improve seed germination indices, which would therefore result in improved percentage and speed of seed germination, followed by faster coleoptile and seedling growth, higher seedling dry weight and seed vigor. These data also illustrated that seed disinfection in the Pishgam and Haydari cultivars had inhibitory effects upon coleoptile growth and seedling length, which could be related to the fungicide’s chemical composition. Unlike other cultivars, disinfection did not show a significant effect on the Soissons cultivar. Based on our data, in order to improve both the speed of wheat seed germination and subsequent plant growth and development; it is necessary to select high-quality, large seeds, planted at a specific planting depth, which have been treated with an effective disinfectant; all of which will be specific for the wheat cultivar in question. Overall, the current study has provided useful information on the effect size seed, sowing depth, and disinfection have upon germination characteristics and seedling growth of wheat cultivars, which can form the basis for future field scale trails.Published onlin

Oleuropein as An Effective Suppressor of Inflammation and MicroRNA-146a Expression in Patients with Rheumatoid Arthritis

Objective: Rheumatoid arthritis (RA) is a common progressive autoimmune disorder that causes chronic inflammationof the joints and damage to other organs. Previous studies have reported the important role of miRNA-146a in thepathogenesis of RA. In addition, the anti-inflammatory and modulatory effects of oleuropein (OLEU) on the expressionpattern of microRNAs (miRNAs) have been shown in different diseases. Therefore, this study aimed to evaluate boththe sensitivity and specificity of miRNA-146a and determine the potential effects of OLEU on the expression levels ofmiRNA-146a and tumour necrosis factor-alpha (TNF-α) in RA patients.Materials and Methods: The participants in this experimental study were divided into 2 groups: RA (n=45) and healthycontrols (n=30). The isolated peripheral blood mononuclear cells (PBMCs) were treated with different concentrationsof OLEU; and the level of TNF-α expression, anti-citrullinated protein, and miRNA-146a were determined usingenzyme-linked immunoassay and real-time polymerase chain reaction, respectively. In addition, the receiver operatingcharacteristic (ROC) curve analysis evaluated the sensitivity and specificity of miRNA-146a in RA patients.Results: Results revealed a positive correlation between the levels of miRNA-146a expression with the serum levels ofC-reactive protein (CRP) and rheumatoid factor (RF) in RA patients. In addition, OLEU treatment decreased the levelsof TNF-α and miRNA-146a expression in treated PBMCs samples compared with untreated cells. The ROC curveanalysis showed an 85% sensitivity and 100% specificity of miRNA-146a in RA patients.Conclusion: Therefore, miRNA-146a can be used as a useful biomarker for RA diagnosis, particularly for earlydetection. In addition, OLEU could suppress inflammation in RA patients through the regulation of miRNA-146a

Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-Adjusted life-years for 29 cancer groups, 1990 to 2017 : A systematic analysis for the global burden of disease study

Importance: Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data. Objective: To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning. Evidence Review: We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-Adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence. Findings: In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572000 deaths and 15.2 million DALYs), and stomach cancer (542000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601000 deaths and 17.4 million DALYs), TBL cancer (596000 deaths and 12.6 million DALYs), and colorectal cancer (414000 deaths and 8.3 million DALYs). Conclusions and Relevance: The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care. © 2019 American Medical Association. All rights reserved.Peer reviewe

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Background: In an era of shifting global agendas and expanded emphasis on non-communicable diseases and injuries along with communicable diseases, sound evidence on trends by cause at the national level is essential. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic scientific assessment of published, publicly available, and contributed data on incidence, prevalence, and mortality for a mutually exclusive and collectively exhaustive list of diseases and injuries. Methods: GBD estimates incidence, prevalence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) due to 369 diseases and injuries, for two sexes, and for 204 countries and territories. Input data were extracted from censuses, household surveys, civil registration and vital statistics, disease registries, health service use, air pollution monitors, satellite imaging, disease notifications, and other sources. Cause-specific death rates and cause fractions were calculated using the Cause of Death Ensemble model and spatiotemporal Gaussian process regression. Cause-specific deaths were adjusted to match the total all-cause deaths calculated as part of the GBD population, fertility, and mortality estimates. Deaths were multiplied by standard life expectancy at each age to calculate YLLs. A Bayesian meta-regression modelling tool, DisMod-MR 2.1, was used to ensure consistency between incidence, prevalence, remission, excess mortality, and cause-specific mortality for most causes. Prevalence estimates were multiplied by disability weights for mutually exclusive sequelae of diseases and injuries to calculate YLDs. We considered results in the context of the Socio-demographic Index (SDI), a composite indicator of income per capita, years of schooling, and fertility rate in females younger than 25 years. Uncertainty intervals (UIs) were generated for every metric using the 25th and 975th ordered 1000 draw values of the posterior distribution. Findings: Global health has steadily improved over the past 30 years as measured by age-standardised DALY rates. After taking into account population growth and ageing, the absolute number of DALYs has remained stable. Since 2010, the pace of decline in global age-standardised DALY rates has accelerated in age groups younger than 50 years compared with the 1990–2010 time period, with the greatest annualised rate of decline occurring in the 0–9-year age group. Six infectious diseases were among the top ten causes of DALYs in children younger than 10 years in 2019: lower respiratory infections (ranked second), diarrhoeal diseases (third), malaria (fifth), meningitis (sixth), whooping cough (ninth), and sexually transmitted infections (which, in this age group, is fully accounted for by congenital syphilis; ranked tenth). In adolescents aged 10–24 years, three injury causes were among the top causes of DALYs: road injuries (ranked first), self-harm (third), and interpersonal violence (fifth). Five of the causes that were in the top ten for ages 10–24 years were also in the top ten in the 25–49-year age group: road injuries (ranked first), HIV/AIDS (second), low back pain (fourth), headache disorders (fifth), and depressive disorders (sixth). In 2019, ischaemic heart disease and stroke were the top-ranked causes of DALYs in both the 50–74-year and 75-years-and-older age groups. Since 1990, there has been a marked shift towards a greater proportion of burden due to YLDs from non-communicable diseases and injuries. In 2019, there were 11 countries where non-communicable disease and injury YLDs constituted more than half of all disease burden. Decreases in age-standardised DALY rates have accelerated over the past decade in countries at the lower end of the SDI range, while improvements have started to stagnate or even reverse in countries with higher SDI. Interpretation: As disability becomes an increasingly large component of disease burden and a larger component of health expenditure, greater research and developm nt investment is needed to identify new, more effective intervention strategies. With a rapidly ageing global population, the demands on health services to deal with disabling outcomes, which increase with age, will require policy makers to anticipate these changes. The mix of universal and more geographically specific influences on health reinforces the need for regular reporting on population health in detail and by underlying cause to help decision makers to identify success stories of disease control to emulate, as well as opportunities to improve. Funding: Bill & Melinda Gates Foundation. © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licens

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019 : A systematic analysis for the Global Burden of Disease Study 2019

Background Achieving universal health coverage (UHC) involves all people receiving the health services they need, of high quality, without experiencing financial hardship. Making progress towards UHC is a policy priority for both countries and global institutions, as highlighted by the agenda of the UN Sustainable Development Goals (SDGs) and WHO's Thirteenth General Programme of Work (GPW13). Measuring effective coverage at the health-system level is important for understanding whether health services are aligned with countries' health profiles and are of sufficient quality to produce health gains for populations of all ages. Methods Based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we assessed UHC effective coverage for 204 countries and territories from 1990 to 2019. Drawing from a measurement framework developed through WHO's GPW13 consultation, we mapped 23 effective coverage indicators to a matrix representing health service types (eg, promotion, prevention, and treatment) and five population-age groups spanning from reproductive and newborn to older adults (≥65 years). Effective coverage indicators were based on intervention coverage or outcome-based measures such as mortality-to-incidence ratios to approximate access to quality care; outcome-based measures were transformed to values on a scale of 0–100 based on the 2·5th and 97·5th percentile of location-year values. We constructed the UHC effective coverage index by weighting each effective coverage indicator relative to its associated potential health gains, as measured by disability-adjusted life-years for each location-year and population-age group. For three tests of validity (content, known-groups, and convergent), UHC effective coverage index performance was generally better than that of other UHC service coverage indices from WHO (ie, the current metric for SDG indicator 3.8.1 on UHC service coverage), the World Bank, and GBD 2017. We quantified frontiers of UHC effective coverage performance on the basis of pooled health spending per capita, representing UHC effective coverage index levels achieved in 2019 relative to country-level government health spending, prepaid private expenditures, and development assistance for health. To assess current trajectories towards the GPW13 UHC billion target—1 billion more people benefiting from UHC by 2023—we estimated additional population equivalents with UHC effective coverage from 2018 to 2023. Findings Globally, performance on the UHC effective coverage index improved from 45·8 (95% uncertainty interval 44·2–47·5) in 1990 to 60·3 (58·7–61·9) in 2019, yet country-level UHC effective coverage in 2019 still spanned from 95 or higher in Japan and Iceland to lower than 25 in Somalia and the Central African Republic. Since 2010, sub-Saharan Africa showed accelerated gains on the UHC effective coverage index (at an average increase of 2·6% [1·9–3·3] per year up to 2019); by contrast, most other GBD super-regions had slowed rates of progress in 2010–2019 relative to 1990–2010. Many countries showed lagging performance on effective coverage indicators for non-communicable diseases relative to those for communicable diseases and maternal and child health, despite non-communicable diseases accounting for a greater proportion of potential health gains in 2019, suggesting that many health systems are not keeping pace with the rising non-communicable disease burden and associated population health needs. In 2019, the UHC effective coverage index was associated with pooled health spending per capita (r=0·79), although countries across the development spectrum had much lower UHC effective coverage than is potentially achievable relative to their health spending. Under maximum efficiency of translating health spending into UHC effective coverage performance, countries would need to reach $1398 pooled health spending per capita (US$ adjusted for purchasing power parity) in order to achieve 80 on the UHC effective coverage index. From 2018 to 2023, an estimated 388·9 million (358·6–421·3) more population equivalents would have UHC effective coverage, falling well short of the GPW13 target of 1 billion more people benefiting from UHC during this time. Current projections point to an estimated 3·1 billion (3·0–3·2) population equivalents still lacking UHC effective coverage in 2023, with nearly a third (968·1 million [903·5–1040·3]) residing in south Asia. Interpretation The present study demonstrates the utility of measuring effective coverage and its role in supporting improved health outcomes for all people—the ultimate goal of UHC and its achievement. Global ambitions to accelerate progress on UHC service coverage are increasingly unlikely unless concerted action on non-communicable diseases occurs and countries can better translate health spending into improved performance. Focusing on effective coverage and accounting for the world's evolving health needs lays the groundwork for better understanding how close—or how far—all populations are in benefiting from UHC

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Background Achieving universal health coverage (UHC) involves all people receiving the health services they need, of high quality, without experiencing financial hardship. Making progress towards UHC is a policy priority for both countries and global institutions, as highlighted by the agenda of the UN Sustainable Development Goals (SDGs) and WHO's Thirteenth General Programme of Work (GPW13). Measuring effective coverage at the health-system level is important for understanding whether health services are aligned with countries' health profiles and are of sufficient quality to produce health gains for populations of all ages. Methods Based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we assessed UHC effective coverage for 204 countries and territories from 1990 to 2019. Drawing from a measurement framework developed through WHO's GPW13 consultation, we mapped 23 effective coverage indicators to a matrix representing health service types (eg, promotion, prevention, and treatment) and five population-age groups spanning from reproductive and newborn to older adults (≥65 years). Effective coverage indicators were based on intervention coverage or outcome-based measures such as mortality-to-incidence ratios to approximate access to quality care; outcome-based measures were transformed to values on a scale of 0–100 based on the 2·5th and 97·5th percentile of location-year values. We constructed the UHC effective coverage index by weighting each effective coverage indicator relative to its associated potential health gains, as measured by disability-adjusted life-years for each location-year and population-age group. For three tests of validity (content, known-groups, and convergent), UHC effective coverage index performance was generally better than that of other UHC service coverage indices from WHO (ie, the current metric for SDG indicator 3.8.1 on UHC service coverage), the World Bank, and GBD 2017. We quantified frontiers of UHC effective coverage performance on the basis of pooled health spending per capita, representing UHC effective coverage index levels achieved in 2019 relative to country-level government health spending, prepaid private expenditures, and development assistance for health. To assess current trajectories towards the GPW13 UHC billion target—1 billion more people benefiting from UHC by 2023—we estimated additional population equivalents with UHC effective coverage from 2018 to 2023. Findings Globally, performance on the UHC effective coverage index improved from 45·8 (95% uncertainty interval 44·2–47·5) in 1990 to 60·3 (58·7–61·9) in 2019, yet country-level UHC effective coverage in 2019 still spanned from 95 or higher in Japan and Iceland to lower than 25 in Somalia and the Central African Republic. Since 2010, sub-Saharan Africa showed accelerated gains on the UHC effective coverage index (at an average increase of 2·6% [1·9–3·3] per year up to 2019); by contrast, most other GBD super-regions had slowed rates of progress in 2010–2019 relative to 1990–2010. Many countries showed lagging performance on effective coverage indicators for non-communicable diseases relative to those for communicable diseases and maternal and child health, despite non-communicable diseases accounting for a greater proportion of potential health gains in 2019, suggesting that many health systems are not keeping pace with the rising non-communicable disease burden and associated population health needs. In 2019, the UHC effective coverage index was associated with pooled health spending per capita (r=0·79), although countries across the development spectrum had much lower UHC effective coverage than is potentially achievable relative to their health spending. Under maximum efficiency of translating health spending into UHC effective coverage performance, countries would need to reach $1398 pooled health spending per capita (US$ adjusted for purchasing power parity) in order to achieve 80 on the UHC effective coverage index. From 2018 to 2023, an estimated 388·9 million (358·6–421·3) more population equivalents would have UHC effective coverage, falling well short of the GPW13 target of 1 billion more people benefiting from UHC during this time. Current projections point to an estimated 3·1 billion (3·0–3·2) population equivalents still lacking UHC effective coverage in 2023, with nearly a third (968·1 million [903·5–1040·3]) residing in south Asia. Interpretation The present study demonstrates the utility of measuring effective coverage and its role in supporting improved health outcomes for all people—the ultimate goal of UHC and its achievement. Global ambitions to accelerate progress on UHC service coverage are increasingly unlikely unless concerted action on non-communicable diseases occurs and countries can better translate health spending into improved performance. Focusing on effective coverage and accounting for the world's evolving health needs lays the groundwork for better understanding how close—or how far—all populations are in benefiting from UHC